Nothing Special   »   [go: up one dir, main page]

ATE459880T1 - Verfahren zum screening einer substanz zur modulierung der wnt -signalkaskade. - Google Patents

Verfahren zum screening einer substanz zur modulierung der wnt -signalkaskade.

Info

Publication number
ATE459880T1
ATE459880T1 AT02008650T AT02008650T ATE459880T1 AT E459880 T1 ATE459880 T1 AT E459880T1 AT 02008650 T AT02008650 T AT 02008650T AT 02008650 T AT02008650 T AT 02008650T AT E459880 T1 ATE459880 T1 AT E459880T1
Authority
AT
Austria
Prior art keywords
kremen
modulating
screening
substance
wnt signal
Prior art date
Application number
AT02008650T
Other languages
English (en)
Inventor
Christof Niehrs
Bingyu Mao
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of ATE459880T1 publication Critical patent/ATE459880T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT02008650T 2002-04-17 2002-04-17 Verfahren zum screening einer substanz zur modulierung der wnt -signalkaskade. ATE459880T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02008650A EP1355152B1 (de) 2002-04-17 2002-04-17 Verfahren zum Screening einer Substanz zur Modulierung der wnt -Signalkaskade.

Publications (1)

Publication Number Publication Date
ATE459880T1 true ATE459880T1 (de) 2010-03-15

Family

ID=28459480

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02008650T ATE459880T1 (de) 2002-04-17 2002-04-17 Verfahren zum screening einer substanz zur modulierung der wnt -signalkaskade.
AT03746281T ATE493436T1 (de) 2002-04-17 2003-03-28 Therapeutische verwendung von kremen 1 und 2, inhibitoren der kanonischen wnt- signaltransduktionskaskade

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03746281T ATE493436T1 (de) 2002-04-17 2003-03-28 Therapeutische verwendung von kremen 1 und 2, inhibitoren der kanonischen wnt- signaltransduktionskaskade

Country Status (10)

Country Link
US (4) US20050244826A1 (de)
EP (3) EP1355152B1 (de)
JP (2) JP2005523005A (de)
AT (2) ATE459880T1 (de)
CA (1) CA2482634C (de)
DE (2) DE60235524D1 (de)
DK (2) DK1355152T3 (de)
ES (2) ES2342152T3 (de)
IL (3) IL164276A0 (de)
WO (1) WO2003087818A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026720A1 (en) 2003-09-04 2005-03-24 Parivid Llc Methods and apparatus for characterizing polymeric mixtures
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US8367822B2 (en) * 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
US7622553B2 (en) * 2003-11-17 2009-11-24 Merck & Co., Inc. Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
JP5419362B2 (ja) * 2008-02-18 2014-02-19 公益財団法人ヒューマンサイエンス振興財団 活性型ｃｄ４陽性ｔ細胞の検査方法
WO2018107109A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Novel anti-kremen2 antibodies and methods of use
CR20210167A (es) 2017-07-07 2021-05-24 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso de la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
EP3996745A4 (de) * 2019-07-10 2023-04-12 Yale University Zusammensetzungen und verfahren zur verwendung eines humanisierten anti-dkk2-antikörpers
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69133293T2 (de) 1990-12-06 2004-05-27 Affymetrix, Inc., Santa Clara Verfahren und Reagenzien für immobilisierten Polymersynthese in sehr grossem Masstab
US5322933A (en) 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
US5856116A (en) 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
WO1997041854A1 (en) * 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
WO1998018947A1 (en) 1996-10-31 1998-05-07 Smithkline Beecham Corporation Methods for the characterization and selection of rna target motifs that bind compounds of pharmaceutical use
US6107473A (en) * 1997-10-01 2000-08-22 Smithkline Beecham Corporation Kringle-related clone HTHBZ47
US7033780B1 (en) * 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
EP1396543A3 (de) * 1999-07-08 2004-03-31 Research Association for Biotechnology Primer zur Synthese von vollständigen cDNA Klonen und ihre Verwendung
EP1074617A3 (de) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
EP1235837A4 (de) * 1999-11-12 2003-04-16 Human Genome Sciences Inc Kringle-domäne enthaltende polynukleotide, polypeptide und antikörper
US20010036643A1 (en) * 1999-12-06 2001-11-01 Holloway James L. Educational kit and method using tumor necrosis factor-stimulated gene and protein
EP1299412A2 (de) * 2000-06-30 2003-04-09 Incyte Genomics, Inc. Proteinmodifikation und wartungsmoleküle
WO2002066509A2 (en) 2001-02-16 2002-08-29 Genentech, Inc. Treatment involving dkk-1 or antagonists thereof
AU2002342734B2 (en) 2001-05-17 2007-07-26 Oscient Pharmaceuticals Corporation Reagents and methods for modulating Dkk-mediated interactions

Also Published As

Publication number Publication date
DK1355152T3 (da) 2010-06-14
IL164276A (en) 2011-10-31
WO2003087818A3 (en) 2004-02-05
US8227200B2 (en) 2012-07-24
DE60335547D1 (de) 2011-02-10
US20050244826A1 (en) 2005-11-03
JP5068734B2 (ja) 2012-11-07
ES2356438T3 (es) 2011-04-08
DK1529062T3 (da) 2011-02-28
EP1529062B1 (de) 2010-12-29
ATE493436T1 (de) 2011-01-15
EP1355152A1 (de) 2003-10-22
US20110287420A1 (en) 2011-11-24
JP2009145352A (ja) 2009-07-02
EP2218735A1 (de) 2010-08-18
JP2005523005A (ja) 2005-08-04
EP1529062A2 (de) 2005-05-11
ES2342152T3 (es) 2010-07-02
CA2482634C (en) 2014-06-10
EP1355152B1 (de) 2010-03-03
DE60235524D1 (de) 2010-04-15
US7947462B2 (en) 2011-05-24
CA2482634A1 (en) 2003-10-23
IL208179A (en) 2012-03-29
AU2003226745A1 (en) 2003-10-27
WO2003087818A2 (en) 2003-10-23
IL208179A0 (en) 2010-12-30
US20130302339A1 (en) 2013-11-14
US20090192109A1 (en) 2009-07-30
IL164276A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
DK1673475T3 (da) Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt
IL208179A0 (en) Nuckeic acud nolecules encoding human kremen 1 and human kremen 2 and diagnostic and pharmaceutical compositions based thereon
DK1469878T3 (da) FGFR agonister
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
LU91759I2 (fr) Denosumab et ses dérivés pharmaceutique acceptables (PROLIA®)
ATE189957T1 (de) Verwendung von nadph-oxidase-inhibitoren zur herstellung eines arzneimittels zur vorbeugung der arteriosklerose
IS8274A (is) Adamantýlglýsín-grunnaðir tálmar dípeptídýl peptídasa IV og aðferðir
MX9606404A (es) Composiciones farmaceuticas y metodos para formular trasnduccion de señales.
ATE322016T1 (de) Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse
DK0862622T3 (da) Fremgangsmåde til identifikation af forbindelser, der vekselvirker med RAC-proteinkinase
DE60207612D1 (de) Verbindungen zur bilddarstellung der alzheimer-krankenheit
ATE534902T1 (de) Replikationsproteinn ciz1
DE60037126D1 (de) POLYMORPHISMEN DES MENSCHLICHEN HPXR Gens UND IHRE ANWENDUNG IN DIAGNOSE UND THERAPIE
DE60217665D1 (de) Verfahren zur Bestimmung der Aktivität von Thymidinkinase-1 und dessen Verwendung
DE60325695D1 (de) Der eaat2-promotor und dessen verwendung
EP1255110A3 (de) Verfahren und Produkten zur Identifizierung von Modulatoren der P2X7-Rezeptorwirkzamkeit, und ihre Verwendung zur Behandlung von Skelettstörungen
DE69912452D1 (de) Verfahren zur prüfung der toxizität von chemischen verbindungen unter verwendung von gastropoda
DE69809785D1 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
DE602006020601D1 (de) Verfahren zur verwendung von il-21
WO2003068932A8 (en) Method for crystallizing human gsk3 and novel crystal structure thereof
ATE462699T1 (de) Substituierte 4,5,6,7-tetrahydro-benzothiazol-2- ylamin-verbindungen
WO2006000464A3 (de) Verfahren zum auffinden schmerzrelevanter substanzen unter verwendung schmerzrelevanter proteine
Chien et al. Albers, HE, see Ehlen, JC,(147) 36 Ávila, DS, see Tomazetti, J.,(147) 29
AU6521898A (en) Substances to correct aberrant gene product fonction

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355152

Country of ref document: EP